# Alnylam Pharmaceuticals clinical trials: 84 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 84 trials with Alnylam Pharmaceuticals as lead sponsor, 17 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alnylam Pharmaceuticals: 84 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/alnylam-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 84
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 84, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 9, 2026 | NCT07636811 | A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Alnylam Pharmaceuticals | Phase 2 | Recruiting | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636811) |
| June 3, 2026 | NCT07624071 | A Study to Evaluate ALN-6222 in Participants With Obesity | Alnylam Pharmaceuticals | Phase 1 | Recruiting | Obesity | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624071) |
| May 8, 2026 | NCT07575308 | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | Alnylam Pharmaceuticals | Phase 2 | Recruiting | Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575308) |
| April 28, 2026 | NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | Alnylam Pharmaceuticals | Phase 2 | Recruiting | Hypertension | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553442) |
| April 17, 2026 | NCT07535606 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | Alnylam Pharmaceuticals | Phase 1 | Active not recruiting | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535606) |
| March 11, 2026 | NCT07465224 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus | Alnylam Pharmaceuticals | Phase 2 | Active not recruiting | Type 2 Diabetes Mellitus (T2DM) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465224) |
| March 11, 2026 | NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Alnylam Pharmaceuticals | Phase 1/2 | Recruiting | Obesity | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463846) |
| January 22, 2026 | NCT07358078 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | Alnylam Pharmaceuticals | Observational | Recruiting | Transthyretin Amyloidosis With Cardiomyopathy | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358078) |
| December 22, 2025 | NCT07295717 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | Alnylam Pharmaceuticals | Phase 1 | Recruiting | Healthy Volunteers | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295717) |
| October 31, 2025 | NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With... | Alnylam Pharmaceuticals | Phase 3 | Recruiting | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223203) |
| October 9, 2025 | NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | Alnylam Pharmaceuticals | Phase 1 | Recruiting | Alzheimer's Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214727) |
| September 18, 2025 | NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for... | Alnylam Pharmaceuticals | Phase 3 | Recruiting | High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk | 11,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181109) |
| July 8, 2025 | NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Alnylam Pharmaceuticals | Phase 3 | Recruiting | Transthyretin Amyloidosis With Cardiomyopathy | 2,250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052903) |
| February 25, 2025 | NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Alnylam Pharmaceuticals | Phase 1/2 | Active not recruiting | Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06845202) |
| November 8, 2024 | NCT06679946 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Alnylam Pharmaceuticals | Phase 3 | Enrolling by invitation | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679946) |
| November 5, 2024 | NCT06675565 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers | Alnylam Pharmaceuticals | Phase 1 | Completed | Healthy Volunteers | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675565) |
| October 26, 2024 | NCT06659640 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Alnylam Pharmaceuticals | Phase 1/2 | Active not recruiting | Hereditary Hemorrhagic Telangiectasia | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06659640) |
| September 19, 2024 | NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Alnylam Pharmaceuticals | Phase 1 | Recruiting | Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06600321) |
| September 5, 2024 | NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Alnylam Pharmaceuticals | Phase 1 | Recruiting | Huntington's Disease | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585449) |
| May 21, 2024 | NCT06423352 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension | Alnylam Pharmaceuticals | Phase 1/2 | Completed | Mild to Moderate Hypertension | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423352) |
| May 1, 2024 | NCT06393712 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | Alnylam Pharmaceuticals | Phase 2 | Active not recruiting | Cerebral Amyloid Angiopathy | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393712) |
| April 11, 2024 | NCT06360289 | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and... | Alnylam Pharmaceuticals | Observational | Active not recruiting | Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic Carrier State | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06360289) |
| February 22, 2024 | NCT06272487 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care... | Alnylam Pharmaceuticals | Phase 2 | Completed | High Cardiovascular Risk, Hypertension | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06272487) |
| March 9, 2023 | NCT05761301 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | Alnylam Pharmaceuticals | Phase 1/2 | Terminated | Type 2 Diabetes Mellitus (T2DM) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05761301) |
| December 22, 2022 | NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects | Alnylam Pharmaceuticals | Phase 1 | Completed | Transthyretin-Mediated Amyloidosis | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05661916) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 10 |
| Phase 2 | 20 |
| Phase 3 | 15 |
| Not applicable | 4 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 43 |
| Recruiting | 17 |
| Terminated | 10 |
| Active not recruiting | 8 |
| Approved for marketing | 3 |
| Withdrawn | 1 |
| No longer available | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Amyloidosis | 14 |
| Amyloidosis, Hereditary, Transthyretin-Related | 12 |
| Amyloidosis, Familial | 10 |
| Cardiomyopathies | 9 |
| Amyloid Neuropathies, Familial | 9 |
| Hypertension | 7 |
| Porphyria, Acute Intermittent | 6 |
| Porphyrias | 6 |
| Amyloid Neuropathies | 6 |
| Hyperoxaluria, Primary | 6 |
| Coproporphyria, Hereditary | 6 |
| Primary hyperoxaluria type 1 | 5 |
| Alzheimer Disease | 5 |
| Obesity | 4 |
| Polyneuropathies | 4 |
| Hyperoxaluria | 4 |
| Metabolic Diseases | 3 |
| Genetic Diseases, Inborn | 3 |
| Metabolism, Inborn Errors | 3 |
| Respiratory Syncytial Virus Infections | 3 |
| Porphyria, Variegate | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Heart Failure | 3 |
| Neurodegenerative Diseases | 2 |
| Kidney Diseases | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [Aggregate suppliers in the United States](https://specstream.ai/data/businesses/aggregate-suppliers/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
